These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 8443402

  • 1. Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.
    Milovanovic SR, Radulovic S, Schally AV.
    Breast Cancer Res Treat; 1992; 24(2):147-58. PubMed ID: 8443402
    [Abstract] [Full Text] [Related]

  • 2. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
    Srkalovic G, Szende B, Redding TW, Groot K, Schally AV.
    Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866
    [Abstract] [Full Text] [Related]

  • 3. Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.
    Milovanovic SR, Monje E, Szepeshazi K, Radulovic S, Schally A.
    J Cancer Res Clin Oncol; 1993 Dec; 119(5):273-8. PubMed ID: 8382705
    [Abstract] [Full Text] [Related]

  • 4. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.
    Srkalovic G, Wittliff JL, Schally AV.
    Cancer Res; 1990 Mar 15; 50(6):1841-6. PubMed ID: 2155060
    [Abstract] [Full Text] [Related]

  • 5. Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.
    Szepeshazi K, Schally AV, Halmos G, Szoke B, Groot K, Nagy A.
    Breast Cancer Res Treat; 1996 Mar 15; 40(2):129-39. PubMed ID: 8879679
    [Abstract] [Full Text] [Related]

  • 6. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer.
    Fekete M, Wittliff JL, Schally AV.
    J Clin Lab Anal; 1989 Mar 15; 3(3):137-47. PubMed ID: 2569034
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo.
    Szepeshazi K, Schally AV, Juhasz A, Nagy A, Janaky T.
    Anticancer Drugs; 1992 Apr 15; 3(2):109-16. PubMed ID: 1388062
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
    Yano T, Pinski J, Radulovic S, Schally AV.
    Proc Natl Acad Sci U S A; 1994 Mar 01; 91(5):1701-5. PubMed ID: 8127868
    [Abstract] [Full Text] [Related]

  • 10. Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
    Szepeshazi K, Schally AV, Nagy A, Halmos G, Groot K.
    Anticancer Drugs; 1997 Nov 01; 8(10):974-87. PubMed ID: 9436641
    [Abstract] [Full Text] [Related]

  • 11. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
    Segal-Abramson T, Kitroser H, Levy J, Schally AV, Sharoni Y.
    Proc Natl Acad Sci U S A; 1992 Mar 15; 89(6):2336-9. PubMed ID: 1312718
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
    Redding TW, Schally AV.
    Proc Natl Acad Sci U S A; 1983 Mar 15; 80(5):1459-62. PubMed ID: 6219395
    [Abstract] [Full Text] [Related]

  • 13. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
    Fekete M, Zalatnai A, Schally AV.
    Cancer Lett; 1989 May 15; 45(2):87-91. PubMed ID: 2567204
    [Abstract] [Full Text] [Related]

  • 14. Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer.
    Srkalovic G, Schally AV, Wittliff JL, Day TG, Jenison EL.
    Int J Oncol; 1998 Mar 15; 12(3):489-98. PubMed ID: 9472084
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
    Halmos G, Schally AV, Kahan Z.
    Int J Oncol; 2000 Aug 15; 17(2):367-73. PubMed ID: 10891548
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.
    Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K, Clarke R, Comaru-Schally AM, Schally AV.
    Breast Cancer Res Treat; 1992 Aug 15; 21(1):35-45. PubMed ID: 1391973
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro.
    Szöke B, Horváth J, Halmos G, Rékási Z, Groot K, Nagy A, Schally AV.
    Peptides; 1994 Aug 15; 15(2):359-66. PubMed ID: 8008640
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.